Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?

Alejandro Moles‐Fernández(Vall d'Hebron Institute of Oncology), Laura Duran-Lozano(Vall d'Hebron Institute of Oncology), Gemma Montalban(Vall d'Hebron Institute of Oncology), Sandra Bonache(Vall d'Hebron Institute of Oncology), Irene López‐Perolio(Centro de Investigación Biomédica en Red de Cáncer), Mireia Menéndez(Institut d'Investigació Biomédica de Bellvitge), Marta Santamariña(Centro de Investigación Biomédica en Red), Raquel Behar(Centro de Investigación Biomédica en Red de Cáncer), Ana Blanco(Servicio Gallego de Salud), Estela Carrasco(Vall d'Hebron Institute of Oncology), Adrià López‐Fernández(Vall d'Hebron Hospital Universitari), Neda Stjepanovic(Vall d'Hebron Institute of Oncology), Judith Balmañà(Vall d'Hebron Hospital Universitari), Gabriel Capellá(Institut d'Investigació Biomédica de Bellvitge), Marta Pineda(Institut Català d'Oncologia), Ana Vega(Fundación Pública Galega de Medicina Xenómica), Conxi Lázaro(Institut d'Investigació Biomédica de Bellvitge), Miguel de la Hoya(Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Orland Dı́ez(Vall d'Hebron Institute of Oncology), Sara Gutiérrez‐Enríquez(Vall d'Hebron Institute of Oncology)
Frontiers in Genetics
September 5, 2018
Cited by 64Open Access
Full Text

Abstract

In silico tools for splicing defect prediction have a key role to assess the impact of variants of uncertain significance. Our aim was to evaluate the performance of a set of commonly used splicing in silico tools comparing the predictions against RNA in vitro results. This was done for natural splice sites of clinically relevant genes in hereditary breast/ovarian cancer (HBOC) and Lynch syndrome. A study divided into two stages was used to evaluate SSF-like, MaxEntScan, NNSplice, HSF, SPANR and dbscSNV tools. A discovery dataset of 99 variants with unequivocal results of RNA in vitro studies, located in the 10 exonic and 20 intronic nucleotides adjacent to exon-intron boundaries of BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, ATM, BRIP1, CDH1, PALB2, PTEN, RAD51D, STK11 and TP53, was collected from four Spanish cancer genetic laboratories. The best stand-alone predictors or combinations were validated with a set of 346 variants in the same genes with clear splicing outcomes reported in the literature. Sensitivity, specificity, accuracy, negative predictive value (NPV) and Mathews Coefficient Correlation (MCC) scores were used to measure the performance. The discovery stage showed that HSF and SSF-like were the most accurate for variants at the donor and acceptor region, respectively. The further combination analysis revealed that HSF, HSF+SSF-like or HSF+SSF-like+MES achieved a high performance for predicting the disruption of donor sites, and SSF-like or a sequential combination of MES and SSF-like for predicting disruption of acceptor sites. The performance confirmation of these last results with the validation dataset, indicated that the highest sensitivity, accuracy and NPV (99.44%, 99.44% and 96.88, respectively) were attained with HSF+SSF-like or HSF+SSF-like+MES for donor sites and SSF-like (92.63%, 92.65% and 84.44, respectively) for acceptor sites. We provide recommendations for combining algorithms to conduct in silico splicing analysis that achieved a high performance. The high negative predictive value obtained allows to select the variants in which the study by in vitro RNA analysis is mandatory against those with a negligible probability of being spliceogenic. Our study also shows that the performance of each specific predictor varies depending on whether the natural splicing sites are donors or acceptors.


Related Papers

No related papers found

Powered by citation graph analysis